drugset / Trial / NCT05511922
PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a multicenter pharmacokinetic (PK) subtrial to investigate the PK profile of KVD900 (sebetralstat) in adolescent patients 12 to 17 years of age with Hereditary Angioedema (HAE) type I or II.
Timeline
- Start
- 2022-10-24
- Primary completion
- 2026-05-27
- Completion
- 2026-05-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sebetralstat | Small molecule | 300 mg | — |
| Subject | Sebetralstat | Small molecule | 600 mg | — |